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Gene expression modules in primary breast
cancers as risk factors for organotropic
patterns of first metastatic spread: a case
control study
Katherine Lawler1,2, Efterpi Papouli3, Cristina Naceur-Lombardelli4, Anca Mera4,5, Kayleigh Ougham6, Andrew Tutt7,
Siker Kimbung8,9, Ingrid Hedenfalk8,9, Jun Zhan10, Hongquan Zhang10, Richard Buus11, Mitch Dowsett11,
Tony Ng1,7,12,13, Sarah E. Pinder4, Peter Parker1,14, Lars Holmberg5,15, Cheryl E. Gillett4, Anita Grigoriadis1,4,6,7*†
and Arnie Purushotham1,4*†
Abstract
Background: Metastases from primary breast cancers can involve single or multiple organs at metastatic disease
diagnosis. Molecular risk factors for particular patterns of metastastic spread in a clinical population are limited.
Methods: A case-control design including 1357 primary breast cancers was used to study three distinct clinical
patterns of metastasis, which occur within the first six months of metastatic disease: bone and visceral metasynchronous
spread, bone-only, and visceral-only metastasis. Whole-genome expression profiles were obtained using whole genome
(WG)-DASL assays from formalin-fixed paraffin-embedded (FFPE) samples. A systematic protocol was developed for
handling FFPE samples together with stringent data quality controls to identify robust expression profiling data. A panel
of published and novel gene sets were tested for association with these specific patterns of metastatic spread and odds
ratios (ORs) were calculated.
Results: Metasynchronous metastasis to bone and viscera was found in all intrinsic breast cancer subtypes, while
immunohistochemically (IHC)-defined receptor status and specific IntClust subgroups were risk factors for visceral-only or
bone-only first metastases. Among gene modules, those related to proliferation increased the risk of metasynchronous
metastasis (OR (95% CI) = 2.3 (1.1–4.8)) and visceral-only first metastasis (OR (95% CI) = 2.5 (1.2–5.1)) but not bone-only
metastasis (OR (95% CI) = 0.97 (0.56–1.7)). A 21-gene module (BV) was identified in estrogen-receptor-positive breast
cancers with metasynchronous metastasis to bone and viscera (area under the curve = 0.77), and its expression increased
the risk of bone and visceral metasynchronous spread in this population. BV was further orthogonally validated with
NanoString nCounter in primary breast cancers, and was reproducible in their matched lymph nodes metastases and an
external cohort.
Conclusion: This case-control study of WG-DASL global expression profiles from FFPE tumour samples, after careful
quality control and RNA selection, revealed that gene modules in the primary tumour have differing risks for clinical
patterns of metasynchronous first metastases. Moreover, a novel gene module was identified as a putative risk factor for
metasynchronous bone and visceral first metastatic spread, with potential implications for disease monitoring and
treatment planning.
Keywords: Breast cancer, Metasynchronous metastases, Gene expression pattern
* Correspondence: anita.grigoriadis@kcl.ac.uk; EA-Purushotham@kcl.ac.uk
†Equal contributors
1School of Cancer Studies, CRUK King’s Health Partners Centre, King’s College
London, Guy’s Campus, London SE1 1UL, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lawler et al. Breast Cancer Research  (2017) 19:113 
DOI 10.1186/s13058-017-0881-y
Background
Development of metastatic breast cancer is a complex
multi-step process manifesting with diverse temporal
patterns involving single or multiple organs [1]. Metastases
to multiple bone or visceral sites may be recorded as syn-
chronous (reported at the same time), metasynchronous
(where reported metastases are separated by a short time
period, typically months) or asynchronous events with a
significant delay between distant recurrences [2–4]. The
median survival of patients with metastatic breast cancer is
18 to 24 months, although the range in survival spans be-
tween a few months and many years and often depends on
the pattern or burden of metastatic spread. Most clinicians
recommend initial treatment with chemotherapy for rap-
idly progressive visceral disease or in women with severe
symptoms related to metastatic breast cancer [5]. Patients
with bone metastases are often treated with osteoclast in-
hibitors, as these agents have been shown to reduce the
risk of skeletal related events such as fractures, the need
for surgery or radiation to bone, spinal cord compression,
and hypercalcaemia of malignancy. However, patients at
risk of metasynchronous metastatic spread to bone and
viscera may benefit from an alternative treatment strategy
at the time of first metastatic presentation. Clinicians may
pursue more aggressive therapy immediately (e.g. chemo-
therapy instead of endocrine therapy) in patients with bone
metastasis who are at high likelihood of imminent visceral
metastasis, or similarly add bone-directed therapy in pa-
tients with visceral metastasis who are at high likelihood of
imminent bone metastasis. Identification of these patients
at an early stage after primary diagnosis or during early
metastatic disease is not well-established.
Various prognostic factors influence the overall sur-
vival of patients with metastatic breast cancer, including
hormone receptor status and axillary lymph node status
at diagnosis, previous adjuvant chemotherapy, and the
number of involved organs [6, 7]. ER-positive disease
has a predilection to metastasise to bone, whereas basal-
like and claudin-low breast cancers are associated with
brain and lung relapses as first site of metastasis and hu-
man epidermal growth factor receptor 2 (HER2)-positive
tumours have a predilection to cerebellar metastasis
[8–14]. Transcriptional features present in the primary
invasive breast carcinoma can be intrinsic to metastatic
progression [15] and are currently tested in clinical trials
for patient stratification for treatment regimens [16, 17].
IntClust subtypes can stratify patients by disease-specific
survival [18], but without attribution to specific metastatic
patterns. Recently small-scale studies suggested circulating
tumour-derived exosomes to be predictive of metastasis to
individual bone or visceral metastatic sites [19]. It remains
unclear, however, to what extent the primary tumour at
the time of diagnosis confers risk factors for clinical pat-
terns of disease progression, manifesting as diverse
temporal patterns of metastatic spread to single or mul-
tiple different organ sites.
With the increasing use of small diagnostic biopsy pro-
cedures prior to systemic treatment in cancer patients,
there are limited opportunities to also collect frozen tis-
sue. The latter has been the prime resource for genomic
analysis and subsequent publication of gene signatures
for prognostic and predictive use. However, despite the
potentially vast resource available within diagnostic
formalin-fixed paraffin-embedded (FFPE) archives, they
have remained largely untapped for exploratory genome-
scale biomarker studies. The quality of RNA from FFPE
material has been the key limitation to its subsequent use.
Whilst modifications to the extraction techniques con-
tinue to make slight improvements to the degraded RNA,
there have been greater developments in array-based gene
expression profiling assays and emerging technologies
for transcriptome sequencing from FFPE samples [20].
The Illumina Whole-Genome DASL (WG-DASL) assay
is one such assay [21]. Several technical studies re-
ported that DASL assays can produce reliable expres-
sion profiles from FFPE tumour tissue samples, given
adequate RNA quality, and design and preprocessing of
the resulting data [21–28].
Here, we designed a whole-genome expression profiling
study using a case-control design to include primary inva-
sive breast cancers with three clinically observed patterns
of metastatic spread: (1) metasynchronous bone and vis-
ceral metastases (within 6 months of first metastasis); (2)
bone only, with delayed or no visceral metastasis; and (3)
viscera only, with delayed or no bone metastasis. Given
the comprehensive time and detailed organ-site informa-
tion in our cohort from which cases and controls were se-
lected, we aimed to identify intrinsic molecular features of
primary breast carcinomas associated with the distinct
patterns of first metastatic spread observed in the clinic,
and in particular those with metasynchronous bone and
visceral metastases.
Methods
Study population, study design, and patient selection
The study population comprised 5061 patients diagnosed
with invasive primary breast cancer without distant metas-
tasis at the time of diagnosis between 1975 and 2005 from
Guy’s Hospital, London UK. All patients had given con-
sent for analysis of their tumour tissues. Median follow up
was 11 years (time between entry and exit dates in the
case-control design).
Three metastatic populations were defined according
to the site and specificity of recurrence: (1) first recur-
rence to bone only, with no other metastatic site within
6 months (“bone-only”), (2) first recurrence to viscera
(other organs) only, with no other metastatic site within
6 months (“visceral-only”), and (3) recurrence to bone
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and viscera within a period of 6 months (“bone and vis-
ceral”). Bone metastasis was defined as distant metasta-
sis to bone or bone marrow, spinal cord compression,
pathological fracture, or hypercalcaemia. Visceral metasta-
sis included distant metastasis to lung, liver, brain, or
ascites. In the study population, 1598/5061 (32%) devel-
oped distant metastasis: 413/1598 (26%) to bone as first
site (bone-only), 747 (47%) to viscera as first site (visceral-
only), and 438 (27%) to bone and viscera within a 6-month
period (bone and visceral).
For each of the three metastatic populations (visceral-only,
bone and visceral, and bone-only), individually matched
controls were randomly sampled using a case-control
incidence-based approach (Additional file 1: Supplementary
methods). Briefly, for each calendar time, T (e.g. 15 January
1999) that a case is diagnosed, one or more controls are
randomly selected from the other members of the cohort
who, at time T, are still at risk of developing the outcome
(distant metastasis). The controls are therefore matched to
the case by time of event. A patient who is a control at one
time can later become a case and/or a control again, and
each of the control series therefore includes a combination
of patients still at risk, which enables efficient estimation of
risks in the clinical population (among 1200 case-control
sets, 75% of patients selected as controls at any calendar
time did not metastasize at all, and 25% went on to have a
distant metastatic event). Case-control sets (n = 400) were
randomly selected for each of the three metastatic popula-
tions, giving a total of 1200 selected case-control sets. Case-
control sets were then selected for tissue assessment and
RNA extraction from FFPE tissue blocks. Extracted RNA
was available for a total of 742 case-control (1:1) pairs: 246
case-control pairs for visceral-only cases, 258 for bone and
visceral cases, and 238 for bone-only cases. An overview of
patient cases is shown in Fig. 1 and a detailed overview of
case-control sampling, random selection, and extracted
case-control pairs is shown in Additional file 2: Figure S1A
and B. Additional file 3: Table S1 tabulates the number of
cases with extracted case:control pairs (1:1), and the
number of matched and unmatched cases and controls
with available gene expression data.
RNA extraction and gene expression profiling
FFPE samples of breast carcinomas were micro-dissected
following tissue review. A total of 1575 FFPE tissue blocks
were assessed (H&E; Additional file 1: Supplementary
methods). Primary tumour blocks from 1357 patients
were taken forward to micro-dissection and RNA extrac-
tion, with a total of 1370 RNA samples (Additional file 2:
Figure S1A). In addition, RNA was extracted from 100
matched positive axillary lymph nodes and from FFPE
samples of six breast cancer cell lines. RNA extraction was
outsourced to Gen-Probe Life Sciences Ltd (Manchester,
UK). RNA sample quality, quantity and integrity were
assessed before proceeding to Illumina HT-12 v4 Bead-
Chips WG-DASL microarray. A detailed description of
tissue selection, micro-dissection, RNA sample selection,
hybridisation design and microarray data processing is
provided in Additional file 1: Supplementary methods.
Two gene expression datasets were produced following
rigorous quality assessment: GWDb (containing primary
tumour samples from 527 patients) and GWDa (con-
taining primary tumour samples from 124 patients,
after removing patients also present in GWDb). Patient
characteristics for GWDb are provided by case-control
series in Table 2. An overview diagram of each dataset
is provided in Additional file 2: Figure S1A. Gene ex-
pression microarray data have been deposited to Array
Express E-MTAB-4003.
Intrinsic subtype assignments and gene module scores
Prediction analysis of microarray 50 (PAM50) intrinsic
subtype was assigned in accordance with Weigelt et al.
[29] using median-centred data and matching probes to
centroid identifiers by gene symbol. The nearest centroid
identified by Spearman correlation was assigned to each
sample. IntClust subtypes were assigned using the iC10
package (v1.1.2) [30] for R/Bioconductor. Gene module
scores for a panel of previously reported gene modules
were estimated using the Denoising Algorithm based on
Relevance network Topology (DART) method [31] and
further compared with weighted sum (weights (+1, −1) ac-
cording to the direction of expression in the gene signa-
ture) (Additional file 1: Supplementary methods).
Previously reported gene expression signatures were
mapped to WG-DASL probes using Ensembl Gene ID,
Entrez Gene ID or gene symbol, according to their ori-
ginal source (Additional file 3: Table S2). Where mul-
tiple microarray probes mapped to a single Entrez
Gene ID, the probe with the most variable gene expres-
sion across the datasets was used (based on standard
deviation in the relevant dataset).
Derivation and expression summary of gene module
To identify a candidate gene module for bone and visceral
metastasis (BV gene module), GWDb was reduced to
ER-positive case-control pairs, and top-ranked genes were
identified using an exploratory differential expression
analysis of the bone and visceral and the no metastasis
groups, as follows. Top-ranked genes were identified by
comparing bone and visceral vs. no metastasis (threshold
false discovery rate (FDR)-adjusted p < 0.2; Mann-Whitney
U test). This procedure resulted in a list of 21 genes
(19 up, 2 down) together with the direction of differen-
tial expression between the bone and visceral and the
no metastasis groups (up, down) which defines the BV
gene module. To inspect the candidate BV module
within expression datasets, the expression of the gene
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module was summarised using a weighted sum with
weights (+1, −1) according to the original direction of
differential expression in the gene module.
NanoString gene expression analysis
For a subset of 192 samples, expression was validated
for 150 selected genes by analysing total RNA (200 ng)
Fig. 1 Overview of cases and gene expression datasets. For each metastatic population (Visceral only, Bone + Visceral, and Bone only) 400 cases were
sampled, and three possible controls were matched to each case by calendar time of event. A random sample of case-control sets was taken forward
to tissue assessment for RNA extraction (Additional file 1: Supplementary methods). Extracted RNA was available for a total of 742 case-control (1:1)
pairs, comprising a total of 1277 individual patients. A detailed overview of patients and samples included in the design and in the gene expression
datasets is shown in Additional file 2: Figure S1A, B
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with the nCounter platform (NanoString Technologies).
Expression data were normalised using the NanoString-
Norm package in R [32]. Background correction was per-
formed by subtracting the negative control probes
(‘mean.2sd’). Expression values were normalised to the
geometric mean of fifteen housekeeping genes. Expression
values were log2-transformed and standardised within
each sample (geometric mean). An expression score for
the BV gene module was calculated among ER-positive
samples using a weighted sum (weights (+1, −1) according
to the direction in the BV module) of mean-centred,
standard deviation-scaled BV genes.
Statistical analysis
For each case-control series, conditional logistic regression
models (modelling individually matched pairs) and logistic
regression models (unconditional, disregarding the case-
control matching) were used to estimate odds ratios (ORs)
and 95% confidence intervals (CIs). For intrinsic molecular
subtypes, ORs were estimated for each subtype compared
with a baseline subtype. Immunohistochemically (IHC)-
derived subtypes were compared with ER-positive, HER2-
negative tumours [33]. PAM50 subtypes were compared
with the luminal A subtype (a good prognosis group [34]).
IntClust subtypes were compared with the baseline
IntClust3 cluster [30]. Gene module scores were scaled
within each case-control series so that 95% of values lay
within the range [−1, 1] [35]. FDR/Benjamini-Hochberg
correction for multiple testing was applied to p values
across the panel of reported gene modules within each test
[36]. A quartile analysis, in which cases were binned ac-
cording to the quartile thresholds of the respective control
series and conditional logistic regression models fitted for
each quartile compared with the first quartile, showed
similar trends in OR to the models that treat gene module
scores as continuous variables (not shown). The Wil-
coxon test for matched pairs and Mann-Whitney U test
(unpaired) was used to test for differences in gene mod-
ule scores between cases and controls in each series. All
statistical analysis was conducted in the R environment
(v3.1.2) (www.r-project.org). Conditional regression models
were fitted using the function clogistic() in the package Epi
(v2.0) [37]:
(Case_Control ~ x + strata(pair.id)).
Logistic regression models were fitted using the func-
tion glm(family = ‘binomial’) in the base package stats.
A Sweave document is provided in Additional file 1:
Supplementary methods.
Results
Patient characteristics and sample processing
Clinico-pathological information for extracted RNA sam-
ples from 742 cases and their case-matched controls are
summarised in Table 1. A rigorous inspection of extracted
RNA and WG-DASL data was performed to ensure that ex-
pression profiles could be obtained across the span of stor-
age times and inferior-quality data were excluded from
further analysis (Additional file 2: Figures S5-7). Primary
tumour samples that passed rigorous WG-DASL quality
controls were assigned to a discovery set (GWDb, 527
patients) or a smaller independent dataset (GWDa, 124
patients) (Additional file 2: Figure S1A, B). Clinico-
pathological information for the three case-control series
in dataset GWDb is shown in Table 2. Before proceeding
to the analyses of the three case-control series, the
clinico-pathological characteristics for each set were
inspected. Patient characteristics in GWDb and GWDa
retained the originally selected distribution of organ-
specific metastatic spread (Additional file 3: Table S1A
lists the number of cases for the case:control pairs
(1:1), and the number of matched and unmatched
cases and controls with available gene expression data).
On inspection of GWDb, there were predominantly IHC-
defined ER-positive breast cancers (~68%), and 18% IHC-
defined HER2-positive and 32% IHC-defined ER-
negative breast cancers. Primary carcinomas were pre-
dominantly treatment-naïve and invasive ductal carcin-
oma of no special histological type. Patients with a bone-
only pattern of first metastatic spread were more likely to
report a visceral metastasis beyond a 6-month period from
first metastasis (37%) than the visceral-only group to a
later bone metastasis (16%) (Additional file 3: Table S1B).
The visceral-only case series had a greater proportion of
grade-3 primary tumours and a smaller proportion re-
ceiving endocrine therapies than the other two case series
in GWDb, while the bone-only case series had the low-
est proportion of patients treated with chemotherapy
(Table 2). Additional file 2: Figure S2 provides an illustra-
tion and descriptive summary of the temporal patterns of
the single and multiple sites of metasynchronous meta-
static spread present amongst all carcinomas in GWDb.
Metastatic spread among breast cancer subtypes
Next we asked to what extent patients with particular
molecular subtypes of breast cancer, as currently defined
in the research setting, were at risk of metasynchronous
bone and visceral, bone-only, or visceral-only patterns of
first metastasis observed in the clinic. Molecular sub-
types in the GWDb set were defined by the IHC-defined
status of ER/HER2 [33], and assigned to the PAM50 [34]
and the IntClust subtypes [18, 30]. Initially, PAM50 esti-
mates for each tumour were compared with IHC-
defined subtypes and overall good accordance was ob-
served: luminal A samples were 89% IHC-defined ER-
positive; 62% of basal-like samples were of the triple-
negative phenotype (IHC-defined ER-negative, PgR-
negative, and HER2-negative; TNBC); and 73% of
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Table 1 Patient characteristics in the case-control series: patients with extracted RNA sample
V cases V controls BV cases BV controls B cases B controls
Number of patients 246 232 258 245 238 222
Number (%)
Age at hist. diagnosis Median (years) 57.1 51.5 55.7 51.0 55.9 51.2
Grade 1 11 (4%) 33 (14%) 7 (3%) 36 (15%) 20 (8%) 20 (9%)
2 81 (33%) 89 (38%) 113 (44%) 127 (52%) 114 (48%) 97 (44%)
3 135 (55%) 87 (38%) 122 (47%) 62 (25%) 81 (34%) 88 (40%)
Unknown 19 (8%) 23 (10%) 16 (6%) 20 (8%) 23 (10%) 17 (8%)
ER IHC status Positive 147 (60%) 160 (69%) 162 (63%) 174 (71%) 188 (79%) 158 (71%)
Negative 99 (40%) 72 (31%) 96 (37%) 71 (29%) 50 (21%) 64 (29%)
PR status Positive 97 (39%) 121 (52%) 116 (45%) 131 (53%) 146 (61%) 113 (51%)
Negative 149 (61%) 111 (48%) 142 (55%) 114 (47%) 92 (39%) 109 (49%)
HER2 status Positive 58 (24%) 35 (15%) 55 (21%) 30 (12%) 35 (15%) 23 (10%)
Negative 108 (44%) 102 (44%) 116 (45%) 98 (40%) 108 (45%) 107 (48%)
Unknown 80 (33%) 95 (41%) 87 (34%) 117 (48%) 95 (40%) 92 (41%)
Tumour size <= 2 cm 96 (40%) 113 (49%) 99 (38%) 136 (56%) 101 (42%) 117 (53%)
>2 cm 146 (60%) 113 (49%) 155 (60%) 101 (41%) 133 (56%) 99 (45%)
Unknown – – 6 (3%) 4 (2%) 8 (3%) 4 (2%) 6 (3%)
Lymph nodes positive 0 51 (21%) 97 (42%) 61 (24%) 109 (44%) 61 (26%) 103 (46%)
1–3 74 (30%) 81 (35%) 64 (25%) 80 (33%) 70 (29%) 64 (29%)
4+ 74 (30%) 28 (12%) 81 (31%) 28 (11%) 64 (27%) 29 (13%)
Unknown 47 (19%) 26 (11%) 52 (20%) 28 (11%) 43 (18%) 26 (12%)
Invasive subtype NOS/no special type 217 (88%) 189 (81%) 219 (85%) 206 (84%) 196 (82%) 189 (85%)
Ductal - mucinous 1 (0%) 3 (1%) 4 (2%) 2 (1%) 1 (0%) 4 (2%)
Ductal - tubular – – 6 (3%) 1 (0%) 7 (3%) 3 (1%) 3 (1%)
Ductal - other 6 (2%) 3 (1%) 1 (0%) 3 (1%) 1 (0%) 3 (1%)
Lobular - classical 14 (6%) 23 (10%) 19 (7%) 22 (9%) 29 (12%) 13 (6%)
Lobular - pleomorphic 3 (1%) 2 (1%) 6 (2%) 3 (1%) 3 (1%) 4 (2%)
Lobular - other 2 (1%) 3 (1%) 3 (1%) 2 (1%) 4 (2%) 1 (0%)
Other 3 (1%) 3 (1%) 5 (2%) – – 1 (0%) 5 (2%)
Surgery type (any time) Breast conserving 58 (24%) 80 (34%) 70 (27%) 82 (33%) 64 (27%) 72 (32%)
Breast conserving +mastectomy 53 (22%) 28 (12%) 56 (22%) 32 (13%) 37 (16%) 27 (12%)
Mastectomy 106 (43%) 110 (47%) 99 (38%) 120 (49%) 115 (48%) 114 (51%)
Unknown 29 (12%) 14 (6%) 33 (13%) 11 (4%) 22 (9%) 9 (4%)
Radiotherapy (adj/neo) Yes 168 (68%) 140 (60%) 197 (76%) 126 (51%) 194 (82%) 125 (56%)
No 78 (32%) 92 (40%) 61 (24%) 119 (49%) 44 (18%) 97 (44%)
Hormone treatment (adj/neo) Yes 204 (83%) 120 (52%) 230 (89%) 130 (53%) 218 (92%) 114 (51%)
No 42 (17%) 112 (48%) 28 (11%) 115 (47%) 20 (8%) 108 (49%)
Chemotherapy Neo-adj only – – 3 (1%) 3 (1%) 67 (27%) 8 (3%) 3 (1%)
Neo-adj and adj 6 (2%) 1 (0%) 9 (3%) 1 (0%) 1 (0%) 2 (1%)
Adj only 146 (59%) 85 (37%) 150 (58%) 2 (1%) 101 (42%) 67 (30%)
No 94 (38%) 143 (62%) 96 (37%) 175 (71%) 128 (54%) 150 (68%)
Hist. histological assessment, ER IHC estrogen receptor status determined by immunohistochemical assessment, PR progesterone receptor, HER2 human epidermal
growth factor receptor 2, adj adjuvant, neo neoadjuvant
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Table 2 Patient characteristics in the case-control series: patients in the discovery cohort GWDb
V cases V controls BV cases BV controls B cases B controls Case series
Number of patients 105 82 106 86 98 90 χ2 p
Age at hist. diag. Median (years) 55.4 52.0 52.5 50.3 55.9 48.8
Grade 1 3 (3%) 12 (15%) 3 (3%) 13 (15%) 8 (8%) 7 (8%)
2 27 (26%) 32 (39%) 44 (42%) 47 (55%) 44 (45%) 42 (47%)
3 68 (65%) 34 (41%) 55 (52%) 19 (22%) 38 (39%) 37 (41%)
Unknown 7 (7%) 4 (5%) 4 (4%) 7 (8%) 8 (8%) 4 (4%) 18.2 0.01
ER IHC status Positive 57 (54%) 52 (63%) 69 (65%) 62 (72%) 77 (79%) 65 (72%)
Negative 48 (46%) 30 (37%) 37 (35%) 24 (28%) 21 (21%) 25 (28%) 13.3 0.001
PR status Positive 39 (37%) 40 (49%) 53 (50%) 56 (65%) 59 (60%) 51 (57%)
Negative 66 (63%) 42 (51%) 53 (50%) 30 (35%) 39 (40%) 39 (43%) 10.9 0.004
HER2 status Positive 31 (30%) 13 (16%) 22 (21%) 13 (15%) 15 (15%) 11 (12%)
Negative 44 (42%) 38 (46%) 51 (48%) 41 (48%) 45 (46%) 42 (47%)
Unknown 30 (29%) 31 (38%) 33 (31%) 32 (37%) 38 (39%) 37 (41%) 7.0 0.1
Tumour size <= 2 cm 41 (39%) 39 (48%) 39 (37%) 44 (51%) 38 (39%) 47 (52%)
>2 cm 64 (61%) 42 (51%) 65 (61%) 38 (44%) 60 (61%) 41 (46%) 0.1 1.0
Unknown – – 1 (1%) 2 (2%) 4 (5%) – – 2 (2%)
Lymph nodes positive 0 15 (14%) 33 (40%) 21 (20%) 32 (37%) 24 (24%) 39 (43%)
1–3 34 (32%) 29 (35%) 31 (29%) 28 (33%) 30 (31%) 30 (33%)
4+ 37 (35%) 10 (12%) 40 (38%) 11 (13%) 26 (27%) 10 (11%)
Unknown 19 (18%) 10 (12%) 14 (13%) 15 (17%) 18 (18%) 11 (12%) 6.1 0.4
Invasive subtype NOS/no special type 96 (91%) 70 (85%) 85 (82%) 73 (85%) 82 (84%) 81 (90%)
Ductal - mucinous – – 2 (2%) 1 (1%) – – 1 (1%) 1 (1%)
Ductal - tubular – – – – 1 (1%) 3 (3%) 2 (2%) 1 (1%)
Ductal - other 1 (1%) 1 (1%) 1 (1%) – – – – 3 (3%)
Lobular - classical 5 (5%) 5 (6%) 7 (7%) 9 (10%) 12 (12%) 2 (2%)
Lobular - pleomorphic 1 (1%) 1 (1%) 6 (6%) – – – – 1 (1%)
Lobular - other – – 2 (2%) 2 (2%) 1 (1%) 1 (1%) – –
Other 2 (2%) 1 (1%) 1 (1%) – – – – 1 (1%) 1.7 0.4 †
Surgery type (any time) Breast conserving 30 (29%) 34 (41%) 35 (33%) 43 (50%) 31 (32%) 39 (43%)
Breast conserving +
mastectomy
17 (16%) 11 (13%) 19 (18%) 7 (8%) 15 (15%) 13 (14%)
Mastectomy 47 (45%) 33 (40%) 41 (39%) 30 (35%) 43 (44%) 35 (39%)
Unknown 11 (10%) 4 (5%) 11 (10%) 6 (7%) 9 (9%) 3 (3%) 1.2 1.0
Radiotherapy (adj/neo) Yes 79 (75%) 52 (63%) 84 (79%) 55 (64%) 82 (84%) 59 (66%)
No 26 (25%) 30 (37%) 22 (21%) 31 (36%) 16 (16%) 31 (34%) 2.2 0.3
Hormone treatment (adj/neo) Yes 84 (80%) 38 (46%) 97 (92%) 57 (66%) 92 (94%) 51 (57%)
No 21 (20%) 44 (54%) 9 (8%) 29 (34%) 6 (6%) 39 (43%) 11.0 0.004
Chemotherapy Neo-adj only – – 2 (2%) 2 (2%) 1 (1%) 5 (5%) 3 (3%)
Neo-adj and adj 4 (4%) – – 4 (4%) 1 (1%) 1 (1%) – –
Adj only 65 (62%) 33 (40%) 67 (63%) 24 (28%) 43 (44%) 28 (31%)
No 36 (34%) 47 (57%) 33 (31%) 60 (70%) 49 (50%) 59 (66%) 8.7 0.01 ‡
Metastatic events in control series No mets, 64 (78%)
V = 8, BV = 8, B = 2
No mets, 66 (77%)
V = 10, BV = 5, B = 5
No mets, 69 (77%)
V = 4, BV = 10, B = 7
†ductal versus lobular, ‡any versus no chemotherapy. Abbreviations as for Table 1
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HER2-enriched samples were IHC-defined HER2-
positive among samples with available IHC status.
Second, the molecular subtypes were tested within
each case-control series using conditional logistic regres-
sion (Additional file 4: Table 3). IHC-defined ER-positive
patients had increased risk of bone-only metastatic
spread and decreased risk of visceral-only and bone and
visceral metastatic spread. In GWDb, patients with the
HER2-enriched PAM50 subtype of breast cancer had in-
creased risk of visceral-only metastatic spread, and pa-
tients with the luminal B subtype had increased risk of
bone-only metastatic spread, compared with patients
with the luminal A subtype as baseline. Patients with tu-
mours classified as IntClust5 had an increased risk of
visceral-only spread compared to those with IntClust3
baseline tumours. Unconditional logistic regression
models had similar OR point estimates (Additional file 5:
Table 4). Patients with the IHC-defined ER-negative/
HER2-positive subtype had an increased risk of
visceral-only and bone and visceral spread compared
to those with ER-positive/HER2-negative carcinomas.
Among IntClust classes with IntClust3 as the reference
class, patients with bone and visceral spread had similar
risks to the visceral-only group with the exception that
IntClust2 and IntClust4 showed increased risk for
visceral-only and bone-only but not bone and visceral
spread. Subtypes found to be risk factors for bone and vis-
ceral spread were also risk factors for visceral-only or
bone-only events from either the conditional or uncondi-
tional logistic regression models, indicating that molecular
subtypes did not confer risks specifically for bone and vis-
ceral events in this study.
Third, the tumour molecular subtypes of all patients
in GWDb were tabulated and compared to the meta-
static pattern of every patient irrespective of the case-
control design, with the aim of providing a descriptive
overview [30] of all primary tumours in GWDb (Fig. 2).
As predicted, IHC-defined ER-negative and HER2-
positive tumours were enriched for the visceral-only
cases, and TNBC was decreased for bone-only events
(Fig. 2, IHC). The breakdown of IHC subtypes in the
bone and visceral group lies in between the bone-only
and visceral-only groups and does not appear to be
dominated by the IHC associations that would be ex-
pected for one case type or the other (bone only or vis-
ceral only). The differences were less clear across the
PAM50 subgroups (Fig. 2, PAM50). IntClust5 had the
highest prevalence of visceral-only events, whereas
IntClust9 followed by IntClust6 had the most bone and vis-
ceral events (Fig. 2, IntClust). The patients in the bone-
only group had mainly ER-positive breast cancers and were
predominantly assigned to IntClust3, 4 and 7 subtypes. In
a
b
Fig. 2 Distribution of three metastatic groups across breast cancer subtypes within the dataset GWDb. Barplots illustrate the proportion of
immunohistochemically defined (IHC), prediction analysis of microarray 50 (PAM50) and IntClust breast cancer subtypes present in each metastatic
group (a) and the proportion of each metastatic group assigned to IHC, PAM50 and IntClust subtypes (b). The patient number for each group is
shown on the top of each column. ER estrogen receptor, HER2 human epidermal growth factor receptor, TNBC triple-negative breast cancer
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contrast, patients with no reported metastases were
enriched for luminal A and IntClust3 subtypes (IntClust in
the “no metastasis” group; χ2, p < 1e-5), and bone and vis-
ceral events were present in all IntClust subtypes (IntClust
in the bone and visceral group; χ2, p = 0.3). In summary,
primary breast cancers with bone and visceral metasyn-
chronous metastatic pattern were found across multiple
molecular breast cancer subtypes in GWDb, indicating
that there was no evidence of increased risk specifically
for bone and visceral events among these current breast
cancer classifications (Additional file 4: Table 3 and
Additional file 5: Table 4).
Prognostic gene modules are indicative of organ-specific
metastatic predilection
Several studies have reported gene expression mod-
ules indicative of particular organ-specific metastatic
spread (reviewed in [38, 39]). We therefore asked
whether some of those modules were also activated
across our three metastatic groups and to what extent
the activation of individual gene modules in the pri-
mary tumour is a risk for the clinically observed pat-
terns of metasynchronous bone and visceral, bone-only,
or visceral-only first metastasis. Primary tumour expres-
sion modules were selected if they were previously re-
ported to be associated with: (i) features of proliferation,
cell motility, presence of stem-cell-like cells and immune/
lymphocytic infiltration, and (ii) organ-specific metastasis
(Additional file 3: Table S2).
The gene modules were each tested as a risk for
each pattern of metastatic spread within GWDb using
conditional logistic regression (Fig. 3a) and logistic re-
gression on complete case-control pairs (Fig. 3b). In
addition, logistic regression models were fitted using
all controls and all cases (to avoid discarding both
samples from a pair due to missing data from
GWDb), and using ER-stratified data with or without
discarding samples from ER-mismatching pairs (Add-
itional file 2: Figure S3). Pairwise correlation of gene
modules confirms that proliferation signatures are highly
correlated in this dataset and there is also correlation be-
tween other modules previously reported to represent me-
tastasis to individual sites and between immune-related
signatures (Fig. 3c), consistent with other studies [35, 40].
The expression of genes associated with proliferation has
been repeatedly shown to be associated with the prognosis
in ER-positive breast cancer [41]. In our study, gene mod-
ules related to proliferation increased the risk of metasyn-
chronous bone and visceral metastasis (e.g. in the
conditional logistic regression model of PTEN module,
OR (95% CI) = 2.3 (1.1–4.8); Additional file 6: Table S3)




Fig. 3 Log (OR) estimated from univariate conditional logistic regression and logistic regression models of illustrative gene modules in the GWDb
dataset for each metastatic group. a Conditional logistic regression (matched pairs). b Logistic regression using complete case-control pairs. Alternating
grey and green bars indicate the broad categorisation of illustrative gene modules (“Proliferation”, “Immune”, etc.) as shown in the module labels on
the left of the plot. c Heatmap of pairwise correlation for a panel of gene modules (Pearson correlation, “complete” clustering; irrespective of
case type or case-control status). Gene modules are listed in Additional file 3: Table S2. ER, estrogen receptor; V, "visceral-only"; BV, "bone and
visceral"; B, "bone-only"; Mets, distant metastasis at any site
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2.5 (1.2–5.1); Additional file 6: Table S3) but not bone-
only metastasis (PTEN, OR (95% CI) = 0.97 (0.56–1.7);
Additional file 6: Table S3). Risk associations were ob-
served by logistic regression modelling within ER-positive
or ER-negative tumours (Additional file 6: Table S3,
Additional file 2: Figure S3A).
In addition, with the alternative aim of providing a
descriptive summary of gene module activation
among all breast carcinomas present in GWDb, two
exploratory analyses were performed irrespective of
the case-control design: tumours with each pattern of
metastatic spread were compared with all tumours with
no metastasis using a logistic regression model (Additional
file 2: Figure S3B), and time to metastasis to individual
sites (lung, liver, bone, brain) was modelled irrespective of
the patterns of first metastatic spread or any other me-
tastases at any time during follow up (Additional file 2:
Figure S3C, D). In agreement with other studies, neither
the logistic regression with reference to tumours with no
metastasis nor the time-to-event analyses can be inter-
preted in the standard epidemiological sense estimating
associations between exposures and outcomes, due to the
sample selection methods employed in this study. These
models are presented here as exploratory hypothesis-
generating tools only with no inference implied for the
breast cancer population. Metastasis to any site was asso-
ciated with proliferation signatures irrespective of ER sta-
tus (Additional file 2: Figure S3C). A number of gene
modules indicated nominal significance but would not
pass a multiple testing correction (Additional file 2:
Figure S3). In IHC-defined ER-negative breast cancers
transforming growth factor (TGF)-β response [42] and
hypoxia response gene sets [43] were activated in carcin-
omas with visceral-only metastases compared with those
that did not metastasise (Additional file 2: Figure S3B),
while TGF-β response and hypoxia response gene sets
were associated with time to lung metastasis (Additional
file 2: Figure S3D). A stem cell module, which is a strong
indicator of short relapse in TNBC [44], was present in
ER-negative breast cancers with visceral-only metastases,
and a module related to intermediate tissue burden and
progression from stemness/basal-like cells [45] was
associated with the visceral-only and bone and vis-
ceral groups, while the low tissue-burden/basal-like
module (derived from metastatic cells from tissues
with low metastatic burden [45]) was under-expressed
in the bone-only group compared with cancers with
no reported metastases. Taken together, while we
were able to recapitulate previously reported associa-
tions between gene signatures and metastasis to bone
or visceral organs within our study, there were no
specific gene module with distinctive risk factors for
the group with clinically observed metasynchronous
bone and visceral spread.
A prognostic gene module for metasynchronous
metastatic spread
As the question remains whether any molecular features
could be identified in primary tumours at the time of
diagnosis for metasynchronous bone and visceral metas-
tases, we then aimed to extract specific gene expression
patterns associated with the bone and visceral metastasis
group. In order to control for interactions between ER
status and metastatic group, the discovery set (GWDb)
was stratified by ER status by removing those case-control
pairs with differing IHC-defined ER status (Additional
file 1: Supplementary methods). We proceeded with a
total of 175 ER-positive breast cancer patients. Explora-
tory differential expression analysis was performed be-
tween the bone and visceral group and tumours that
did not metastasise, and the top-ranked genes (FDR-ad-
justed p < 0.2; see “Methods”) were taken forward for
further exploratory analysis (Additional file 3: Table S4).
In receiver operating characteristic (ROC) curve analysis
the area under the curve (AUC) was 0.77 for a 21-gene set
for the bone and visceral metastasis group (“BV module”;
Fig. 4a, Additional file 3: Table S4), in comparison to an
AUC of 0.66 and 0.56 for visceral-only and bone-only
metastatic spread, respectively, while when combining all
three series, the overall AUC was 0.83 for any metastatic
site (Additional file 2: Figure S4).
The risk of bone and visceral spread from the BV gene
module was next estimated using the bone and visceral
case-control series within GWDb and GWDa (Additional
file 3: Table S5). A significant risk of bone and visceral
spread was observed within GWDb (OR (95% CI) = 6.0
(3.1–12.2). In the independent dataset GWDa, the OR es-
timates were also positive (OR (95% CI) = 1.9 (0.38–9.7),
and there was a shift towards increased BV module scores
in the cases compared to the controls (Mann-Whitney
U test, p = 0.3), however due to the small sample size it
was not significant (Additional file 3: Table S5). To-
gether these results indicated that this BV gene module
might confer an increased risk of the bone and visceral
pattern of metastatic spread.
To further explore the relevance of our BV gene mod-
ule, orthogonal validation of the discovery was obtained
on three levels: (i) with NanoString nCounter, by testing
the expression of these genes in a representative subset
of 192 samples, in which BV module scores were highly
concordant with WG-DASL values (Fig. 4b; Pearson’s
correlation = 0.78, p < 1e-4); (ii) the expression of the BV
gene set was reproduced in matched lymph node metas-
tases within our cohort (Fig. 4c); and (iii) we investigated
the gene expression of the BV module in an external
dataset of lymph node metastases from breast cancers
with known metastatic disease [46]. The BV gene mod-
ule exhibited increased expression in the lymph node
metastases of those patients with a bone and visceral
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pattern of first metastatic spread compared with
visceral-only (Fig. 4d; Mann-Whitney U test, p = 0.04)
and bone-only groups (Fig. 4d; Mann-Whitney U test,
p = 0.1 (not significant)). These results are in line with
our exploratory analyses and together are the first demon-
stration towards developing an intrinsic risk factor in
primary breast cancer for metasynchronous bone and
visceral first distant recurrence. Inspection of the genes
comprising the candidate BV module indicated enrich-
ment for association with condensing chromosomes
and the kinetochore (Additional file 2: Figure S8).
Discussion
Metastasis represents the major cause of death in breast
cancer patients. Over the last few years, numerous
molecular-based prognostic tests of varying specificity
have emerged, indicating that primary breast carcinomas
display expression profiles associated with organ-specific
dissemination; however, few studies have addressed
synchronous and metasynchronous patterns of meta-
static spread [47]. Treatment strategies and monitoring
of patients could potentially be tailored if prediction of
single or multi-organ metastasis could be estimated at
an early stage. As a step towards this goal, this study es-
timated potential risks for particular patterns of metastatic
spread associated with intrinsic subtypes and gene mod-
ules in the primary tumour. A gene expression module
present in primary invasive carcinomas associated with
concurrent or short-term delays between the development
of bone and visceral metastasis was identified and vali-
dated in an independent series of lymph node metastases.
Predilection for metastatic spread in breast cancer has
previously been associated with gene modules enriched
in the primary tumour. A common feature of these are
markers of cell proliferation, such as the GENE70, PTEN,
the centrosomal kinase AURKA [48, 49] and multiple pro-
cesses related to chromosomal instability including CIN70
[50]. In this study, we found that a gene module
Fig. 4 BV module for metasynchronous metastatic spread. a Discovery of the BV module. BV module scores, shown as density plots for each
metastatic group in the estrogen-receptor-positive case-control paired breast cancer cases from the discovery set (GWDb) together with the
corresponding receiver operating characteristic curve for the bone and visceral group. b Estimated BV expression score based on NanoString nCounter
quantification compared with those obtained from the WG-DASL platform. c Correlation plot displaying the BV gene set in primary tumours and their
matched lymph node metastases. Points are colour-coded according to metastatic group. d BV module scores in lymph node metastases of the
GSE46141 data, displayed according to their reported patterns of first metastatic spread
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containing components of the kinetochore (CENPO,
SPC25, CASC5, SKA3, CENPE; Gene Ontology (GO) CC
term “kinetochore”) was associated with the occurrence of
metasynchronous bone and visceral metastases within
6 months of the first metastasis. The regulation of genes
encoding kinetochore components has been hypothesised
to drive chromosomal instability [51], whereby the upreg-
ulation of kinetochore genes may reflect the activation of
a cell division programme [52]. We speculate that the as-
sociation of this gene module with rapid multitropic bone
and visceral spread after first metastasis points to a mech-
anism of chromosomal instability, enabling the develop-
ment of subclones and selection of metastatic tumour
cells for invasion and adaptation at multiple bone and
visceral sites. Gene modules related to proliferation or
mammary stem cells might be expected to influence
the synchronicity of multiple metastases, and were in-
deed found to be significant risks for multiple bone and
visceral first metastases.
Limitations of this study include the imposition of a
timeline that defines metasynchronous metastases: for
example, in our datasets a change in the definition of
metasynchronous from 6 months to 12 months would
have led to 10% of bone-only and 5% of visceral-only
metastases to have been considered metasynchronous
(Additional file 2: Figure S2A), and other definitions of
metasynchronicity could be imposed, which may affect
the estimated risks for each case type. The AUC for the
BV signature was higher for all metastases than for
metasynchronous bone and visceral metastases: from the
point of view of clinical translation, further work would
need to establish whether BV or other putative signatures
for patterns of metastatic spread could add value over exist-
ing signatures such as Oncotype or Mammaprint [16, 17].
Metastasis is a complicated, multi-step process and
our understanding of the multiple factors involved is still
partial. In the last decade, genomic profiling has attempted
to fill this knowledge gap; however, these studies have pri-
marily used fresh-frozen tissue, had restricted numbers of
primary and metastatic cases, and incomplete information
on the site and time to development of the metastatic
spread. This has limited the utility and clinical applicability
of these modules. There is evidence that some tumours
have a predilection for colonising specific tissues in clinical
populations (e.g. [10]), while animal model and recent
next-generation sequencing studies also support a role for
subclonal adaptations to the metastatic niche (e.g. [53]). In
this study, we focused on the tumour as one part of this
complex metastatic cascade, which is close to clinical diag-
nostic practise and patient management. We hypothesised
that intrinsic subtypes and gene modules confer risk of
particular patterns of metastatic spread in some tumours.
We addressed this question by designing a case-control
study for particular patterns of metastatic spread.
Pre-clinical models have contributed to our under-
standing of metastastic spread but they might not cap-
ture many of the processes that are important in a
clinical setting - including alterations to the immune
system or incorporation of specific latency periods to
study multi-organ metastatic spread in parallel - and
many gene signatures originate from ER-negative cell
line and patient-derived xenograft (PDX) models. Mul-
tiple lines of evidence indicate that intrinsic subtypes
and gene modules have different metastatic potential
within clinical populations [18, 54, 55]. We sought to
address whether gene modules could confer risk for
specific temporal patterns of metastatic spread using a
large tumour archive with detailed clinical follow up.
An efficient case-control design is required given that
multiple breast cancer subtypes and metastatic patterns
are present in any clinical population. This study there-
fore focused on three specific patterns of metastatic
spread based on epidemiological observations from the
same clinical population [56].
As recently shown by Iddawela et al. [28] and others,
the WG-DASL platform together with stringent quality
control and data processing steps can produce reliable
results from FFPE breast tumour tissue. Here, by starting
with a well-characterised cohort of 5061 patients with
long-term follow up of whom 1598 developed metasta-
sis, we have created a well-annotated and sufficiently
large cohort to investigate molecular risk factors for
single and multiple organotropic metasynchronous
metastatic disease. While many samples were excluded
during the quality control steps, the processed gene ex-
pression datasets enabled an investigation of gene expres-
sion modules as risk factors for specific patterns of first
metastatic spread.
The use of an incidence-based case-control design en-
sured that non-metastasising primary tumour samples
were also included from the same range of calendar
dates of diagnosis, and enabled efficient estimation of
effects in a standard clinical population. Cunha et al.
[57] recently reported using a case-control design to es-
timate the effect of ALK1 expression in frozen breast
tumours as a molecular risk factor for metastatic spread.
Here, our use of an incidence-based case-control design
enabled the estimation of genome-wide molecular risk
factors for three clinically observed patterns of first meta-
static spread (bone-only, visceral-only, or bone and vis-
ceral within a 6-month time period). Further work on
patterns of long-term disease progression may focus on a
more defined population, such as ER-positive/HER2-
negative or high-grade tumours, and make use of ap-
propriate platforms for assaying fewer FFPE tumour
samples from a stratified clinical population.
Patients at risk of metasynchronous bony and visceral
metastases could potentially profit from closer disease
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monitoring and may benefit from a more radical bisphos-
phonate and chemotherapeutic combination treatment
strategy up front in the metastatic setting. In ER-positive
disease the benefits of hormonal therapy in managing vis-
ceral metastases from breast cancer are much lower than
those offered by chemotherapy. Conversely, Perez et al.
[58] suggest that, in patients with bone metastases, efforts
should be made to select the least aggressive therapy to
avoid excessive toxicity. Progress towards the optimisation
of disease monitoring and treatment strategies fundamen-
tally requires a better understanding of risks that could be
estimated at primary diagnosis, together with an improved
understanding of additional emerging risks as breast
cancers progress to a metastatic setting (for example,
establishment of a metastatic niche). Initiatives such as
AURORA, a large multinational, collaborative metastatic
breast cancer molecular screening programme [59] will
further shed light on our knowledge of whether the gene
expression patterns found in primary breast cancer is
similar to those in metastatic material. This would add to
our understanding of the metastatic process and guide
treatment regimens for metastatic breast cancer. A liver-
selective gene module was among the set of gene modules,
where these genes were under-expressed in primary tu-
mours from patients who subsequently developed liver
metastases, but displayed high expression in the liver me-
tastases [46]. We observed the low-level expression of
these 17 genes in ER-positive cancers, which metastasised
to the liver. Of note, this inverse correlation in the direc-
tion of transcript levels of some genes between primary
tumours and metastases was not unique to this gene
module, but was also seen in another gene module as-
sociated with infiltration of the blood-brain barrier [60]
and has also been recently reported in ovarian cancers
[61]. Due to the scarcity of available samples, a clear
biological conclusion cannot be drawn about such in-
verse correlation and we hypothesise that the process of
adaption to the new microenvironment or development of
the pre-metastatic niche [62, 63] favours those primary
tumour traits. Ultimately, larger cohorts with matched pri-
mary and metastatic lesions are required to elucidate the
clinical relevance of these transcriptional changes after pri-
mary diagnosis.
Conclusions
In conclusion, by analysing gene expression profiles in
a large cohort of well-characterised primary breast car-
cinomas and lymph node metastases in patients with
long-term follow up and detailed information on meta-
static spread, we were able to identify patterns informative
of multiple organotropic metasynchronous metastatic
spread. Further investigations are necessary in order to
tease out the contributing components, which could be
relevant for tailoring systemic therapeutic regimens,
monitoring response or resistance to therapy, and war-
ranting close imaging/biomarker follow up with the insti-
tution of early intervention strategies as required. These
genome-wide expression data across extensive case-
control series will provide a useful resource facilitating
further studies of the biology and clinical relevance of sin-
gle and metasynchronous metastatic spread, and might
enable rational personalised treatment strategies to be de-
veloped for patients at risk of bone or visceral metastasis
with subsequent metasynchronous metastasis.
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